1) Understand how pharma uses the information provided by FDG-PET. 2) Become familiar with site qualification and quality control methods used in clinical trial of an investigational therapeutic agent. 3) Understand why specific clinical trial imaging protocols may differ from clinical practice and importance of adhering to the clinical trial imaging protocol. 4) Realize which issues confound attempts to achieve more quantitative FDG-PET in the context of a clinical trial of an investigational therapeutic agent.
Evelhoch, J,
Lessons Learned from Drug Development Trials Using Molecular Imaging. Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL.
http://archive.rsna.org/2014/12020947.html
